 |
11 Diseases |  |
40 Trials |
|
40 Trials |  |
2608 News |  |
| 12345678910111213...3738» |
- | Journal: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Pubmed Central) - May 15, 2024
The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.
- | Journal: Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. (Pubmed Central) - May 15, 2024
The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA. Interruption of antipsoriatic oral and biologic therapies is generally not necessary for
- | Remicade (infliximab) / J&J, Tremfya (guselkumab) / J&J
Journal: Long-term clinical course of two rare cases of synovitis-acne-pustulosis-hyperostosis-osteomyelitis syndrome involving only unilateral femur. (Pubmed Central) - May 15, 2024
X-rays of the femur showed cortical thickening. SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases.
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Clinical, Retrospective data, Journal: Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. (Pubmed Central) - May 15, 2024
At 6 months after index biologic discontinuation, the guselkumab cohort was 31% and 40% more likely to achieve remission than secukinumab (rate ratio [RR] = 1.31; p < 0.001) and ixekizumab cohorts (RR = 1.40; p < 0.001). Guselkumab was associated with greater persistence and likelihood of remission than IL-17 inhibitors, indicating greater disease control and modification potential.
- || Tremfya (guselkumab) / J&J
P4 data, Journal: Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study. (Pubmed Central) - May 15, 2024
Our findings demonstrate that guselkumab is well tolerated and effective in Japanese patients with psoriasis through 20?weeks of treatment in real-world clinical practice, showing significant effectiveness observed as early as 4?weeks. The study was officially registered with the University Hospital Medical Information Network Clinical Trials Registry with the identifier UMIN000032969.
- || Review, Journal: Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. (Pubmed Central) - May 12, 2024
Low doses, intermittent treatment may increase ADA formation. An appropriate biologic should be selected based on the ADA formation rate and course of treatment.
- | Tremfya (guselkumab) / J&J
Journal: Successful treatment with guselkumab of anti-p200 pemphigoid associated with plaque psoriasis. (Pubmed Central) - May 11, 2024
An appropriate biologic should be selected based on the ADA formation rate and course of treatment. No abstract available
- | Tremfya (guselkumab) / J&J
Journal: Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. (Pubmed Central) - May 11, 2024
Primary and secondary inefficacy were reported by 1 (1.6%) and 5 (8.2%) patients. As regards safety, no severe AEs were collected.
- || Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Clinical, Journal: Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. (Pubmed Central) - May 11, 2024
In contrast, the efficacy of guselkumab does not seem to be affected by the BMI, involvement of fingernails, or location in the genital or scalp area. To sum up, our long-term real-life multicenter retrospective study confirmed the efficacy and safety of guselkumab following ustekinumab discontinuation up to 156 weeks of treatment.
- | Tremfya (guselkumab) / J&J
Journal: Erfolgreiche Behandlung eines Anti?P200?Pemphigoids in Verbindung mit Plaque?Psoriasis mit Guselkumab: Successful treatment with guselkumab of anti?p200 pemphigoid associated with plaque psoriasis. (Pubmed Central) - May 11, 2024
To sum up, our long-term real-life multicenter retrospective study confirmed the efficacy and safety of guselkumab following ustekinumab discontinuation up to 156 weeks of treatment. No abstract available
- | Tremfya (guselkumab) / J&J
Biomarker, Journal: Exposure-response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis. (Pubmed Central) - May 8, 2024
No biomarker candidates were identified through serum proteomics. We propose protein screening should be repeated in larger cohorts to continue the quest for predictive biomarkers.
- || Retrospective data, Review, Journal: Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - May 5, 2024
We propose protein screening should be repeated in larger cohorts to continue the quest for predictive biomarkers. Among all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
New P4 trial: HELIOS: Proactive TDM Versus Standard Use of Biologics in Psoriasis (clinicaltrials.gov) - May 3, 2024
P4, N=210, Not yet recruiting, Sponsor: University Hospital, Ghent
- Tremfya (guselkumab) / J&J
A case of low level viral escape (e-Poster Hall) - Apr 28, 2024 - Abstract #EADVSp2024EADV_Sp_879;
- Tremfya (guselkumab) / J&J
Guselkumab in real clinical practice: achieving a (e-Poster Hall) - Apr 28, 2024 - Abstract #EADVSp2024EADV_Sp_849;
- Tremfya (guselkumab) / J&J
Chronic Psoriasis, Chronic Solution: Long-Term Treatment Success with Guselkumab. Results from a Spanish Cohort (e-Poster Hall) - Apr 28, 2024 - Abstract #EADVSp2024EADV_Sp_834;
- Tremfya (guselkumab) / J&J
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis in real-world practice (e-Poster Hall) - Apr 28, 2024 - Abstract #EADVSp2024EADV_Sp_813;
- Tremfya (guselkumab) / J&J
Guselkumab binding to CD64+ IL-23 (Trinity Exhibit Hall) - Apr 27, 2024 - Abstract #SID2024SID_985;
- Tremfya (guselkumab) / J&J
VISIBLE: Guselkumab (GUS) skin and scalp clearance in skin of color (SOC) participants (pts) by baseline (BL) inflammatory disease burden (Trinity Exhibit Hall) - Apr 27, 2024 - Abstract #SID2024SID_700;
- Tremfya (guselkumab) / J&J
Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial (Trinity Exhibit Hall) - Apr 27, 2024 - Abstract #SID2024SID_200;
- | Tremfya (guselkumab) / J&J
Journal: Guselkumab-induced paradoxical exacerbation of extra-palmoplantar lesions in a patient with palmoplantar pustulosis. (Pubmed Central) - Apr 25, 2024
Among all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively. No abstract available
- | Tremfya (guselkumab) / J&J
Journal: Successful guselkumab treatment of a refractory psoriasis patient with Graves' disease: a case report. (Pubmed Central) - Apr 24, 2024
Finally, switching to guselkumab resulted in the psoriasis lesions significantly improving. These findings suggest that guselkumab might be an effective treatment option for refractory psoriasis combined with GD.
- | Tremfya (guselkumab) / J&J
Journal: Real-life data over 36?weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey. (Pubmed Central) - Apr 24, 2024
This study includes real-life data on the use of guselkumab therapy for psoriasis in the Turkish population. Based on the results, guselkumab is a highly effective and safe treatment.
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Trial completion date, Combination therapy: DUET-CD: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Apr 24, 2024
P2, N=715, Recruiting, Sponsor: Janssen Research & Development, LLC
Based on the results, guselkumab is a highly effective and safe treatment. Trial completion date: Mar 2029 --> Oct 2030
- ||| Tremfya (guselkumab) / J&J
Trial completion date: GRAVITI: A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Apr 24, 2024
P3, N=350, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2029 --> Oct 2030 Trial completion date: Jun 2025 --> Mar 2025
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Trial completion date, Combination therapy: DUET-UC: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Apr 23, 2024
P2, N=550, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2025 --> Mar 2025 Trial completion date: Mar 2029 --> Oct 2029
- | Journal: Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month (Pubmed Central) - Apr 23, 2024
Trial completion date: Mar 2029 --> Oct 2029 This real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month
- || Retrospective data, Review: Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Apr 17, 2024
This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.
- ||| Tremfya (guselkumab) / J&J
Trial termination: ORCHID-LN: A Study of Guselkumab in Participants With Active Lupus Nephritis (clinicaltrials.gov) - Apr 16, 2024
P2, N=33, Terminated, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated; Due to enrollment challenges, J&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.
- | Retrospective data, Journal: Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score. (Pubmed Central) - Apr 15, 2024
The highest rates of persistence with clear or almost clear skin can be expected with guselkumab, ixekizumab and risankizumab compared to other biologics. The proposed proxy definitions of long-term persistence (POR and PSR) are reliable measures of patients being successfully treated that warrant further exploration and validation.
- || Review, Journal: The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. (Pubmed Central) - Apr 15, 2024
All these drugs showed high levels of effectiveness in both clinical trials and real-life experiences, with an excellent profile in terms of safety. Certainly, furthers studies will allow for better characterization of biologics' profile, in order to administer the right drug for the right patients at the right moment.
- | Tremfya (guselkumab) / J&J
Journal: Safety Profile of Guselkumab in Treatment of Patients with Psoriasis and Coexisting Hepatitis B or C: A Multicenter Prospective Cohort Study. (Pubmed Central) - Apr 15, 2024
Certainly, furthers studies will allow for better characterization of biologics' profile, in order to administer the right drug for the right patients at the right moment. No abstract available
- || Tremfya (guselkumab) / J&J
Review, Journal: Dose reduction of biologics in patients with plaque psoriasis: a review. (Pubmed Central) - Apr 12, 2024
Four of the newly found articles tested DR strategies, mostly focusing on first-generation biologics; only guselkumab (IL-23i) was included in one study...In conclusion, DR seems promising, but a research gap still exists in randomized, prospective studies testing DR strategies, especially of IL-17/23i, hampering the completion of guidelines on DR. Taking into account the identified barriers and facilitators most likely results in a more successful implementation of biologic DR in practice.
- | Tremfya (guselkumab) / J&J
Journal: Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study. (Pubmed Central) - Apr 11, 2024
Guselkumab improved overall skin symptoms and HRQoL in patients with psoriasis and decreased sexual impairment and perceived stigmatization. No new safety signals were observed.
- | Tremfya (guselkumab) / J&J
Journal: Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: results from a real-life multicentre cohort. (Pubmed Central) - Apr 10, 2024
The short-term effectiveness of guselkumab in patients with PsA and suggestive features of axial involvement was shown. Although further studies are needed, our multicentre "real-life" study may suggest the clinical usability of guselkumab in this context.
- | Tremfya (guselkumab) / J&J
Journal: Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial. (Pubmed Central) - Apr 10, 2024
P2
The results of this nonrandomized trial suggest that guselkumab has efficacy in treating refractory moderate to severe adult PRP. ClinicalTrials.gov Identifier: NCT03975153.
- || Retrospective data, Review, Journal: Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: A systematic review with network meta-analysis of randomised trials. (Pubmed Central) - Apr 10, 2024
Infliximab has inconsistent clinical response, and more data are necessary to confirm this molecule as a potential third-line therapy in HS. The blockade of IL-23 and CD5a pathways is not relevant, or at least the current evidence is insufficient to recommend further investigation of guselkumab, risankizumab, and vilobelimab in phase III trials.
- | Tremfya (guselkumab) / J&J
Retrospective data, Journal: Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China. (Pubmed Central) - Apr 5, 2024
The blockade of IL-23 and CD5a pathways is not relevant, or at least the current evidence is insufficient to recommend further investigation of guselkumab, risankizumab, and vilobelimab in phase III trials. The head and lower limbs were the areas least responsive to treatment, with PASI
- || Tremfya (guselkumab) / J&J
Trial completion: HiGUS: Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (clinicaltrials.gov) - Apr 4, 2024
P2, N=20, Completed, Sponsor: University Medical Center Groningen
The head and lower limbs were the areas least responsive to treatment, with PASI Unknown status --> Completed
- Tremfya (guselkumab) / J&J
Guselkumab binding to CD64+ IL-23 (Poster Tour 4) - Mar 29, 2024 - Abstract #EULAR2024EULAR_2176;
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Trial completion date, Combination therapy: DUET-CD: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Mar 27, 2024
P2, N=715, Recruiting, Sponsor: Janssen Research & Development, LLC
Unknown status --> Completed Trial completion date: Oct 2030 --> Mar 2029
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Trial completion date, Combination therapy: DUET-UC: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Mar 26, 2024
P2, N=550, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2030 --> Mar 2029 Trial completion date: Aug 2030 --> Mar 2029
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
Retrospective data, Journal: Drug survival of biologics in psoriasis: An Australian multicentre retrospective study. (Pubmed Central) - Mar 21, 2024
To our knowledge, this is the first Australian study to report on outcomes of multiple new biologics that are currently in use for the treatment of chronic plaque psoriasis. Overall, this study provides insight into patterns of care from a local experience that may help guide the management of moderate-to-severe psoriasis.
- | Bimzelx (bimekizumab) / UCB, Tremfya (guselkumab) / J&J
Journal, HEOR: Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 (Pubmed Central) - Mar 15, 2024
P3, P3b
Overall, this study provides insight into patterns of care from a local experience that may help guide the management of moderate-to-severe psoriasis. According to MAICs, bimekizumab demonstrated greater or comparable efficacy on ACR50/70 and MDA outcomes than guselkumab in patients with PsA who were bDMARD-na
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
PK/PD data, Journal, Combination therapy: Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions. (Pubmed Central) - Mar 15, 2024
Combination therapy slightly decreased the clearance of golimumab, but not guselkumab clearance, in patients with UC. Lower immunogenicity and greater improvement of inflammation with combination therapy were potential mechanisms for slightly increased golimumab concentrations with combination therapy as compared with golimumab monotherapy.
- || Humira (adalimumab) / AbbVie, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Clinical, Journal: Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. (Pubmed Central) - Mar 15, 2024
P3
Lower immunogenicity and greater improvement of inflammation with combination therapy were potential mechanisms for slightly increased golimumab concentrations with combination therapy as compared with golimumab monotherapy. Early treatment response and baseline characteristics, including smoking, psoriasis duration, and obesity, may be associated with longer-term response to biologics.
- Tremfya (guselkumab) / J&J
ARGES-CMES: A NOVEL, CONTINOUS SCORING FOR ULCERATIVE COLITIS DISEASE SEVERITY: ASSOCIATION WITH CLINICAL MEASURES AND TREATMENT RESPONSE VARIABLES (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_7538;
P2/3, P3
Arges-CMES, our continuous scoring model, exhibits significant associations with well-established clinical measures and treatment response variables. Its enhanced granularity, compared to human-read MES, holds promise for insightful assessments of clinical outcomes in future trials.
- Tremfya (guselkumab) / J&J
THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6016;
P2/3
The primary endpoint of clinical remission and all 9 major secondary endpoints across clinical, symptomatic, endoscopic, histologic, and patient-reported outcome measures were met with statistical significance by both GUS SC maintenance regimens. Safety results through maintenance Wk44 were consistent with the known and favorable safety profile of GUS in approved indications.
- Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Alofisel (darvadstrocel) / Takeda, Tremfya (guselkumab) / J&J
4435: Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Distinguished Abstract Plenary (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6013;
Description: This session highlights the best of the best in basic and clinical science research submitted to DDW 2024. Learning Objectives: Describe the efficacy and safety of guselkumab, darvadstrocel, and risankizumab for the treatment of IBD
- COMPARATIVE EFFICACY OF BIOLOGICS AND SMALL MOLECULE THERAPIES IN IMPROVING HEALTH RELATED QUALITY OF LIFE IN ULCERATIVE COLITIS; SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_4911;
All medications were superior to placebo except etrolizumab (OR= 0.87 [95% CI 0.39;1.92]) Per SUCRA score, tofacitinib ranked highest (88%), followed by golimumab (77%)...In addition, guselkumab ranked highest followed by tofacitinib and upadacitinib in improving HRQoL. During maintenance of remission, Tofacitinib ranked highest.